0
0
0
0
1
2
3
$0
Is Lam Research solid or fragile? The Finex Financial Health Scanner reads LRCX's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2026) | $23.2B |
|---|---|
| Net income | $7.3B |
| Operating margin | 35.3% |
| Net margin | 31.3% |
| Cash and investments | $5.6B |
| Total debt | $3.7B |
| Free cash flow | $4.5B |
| Revenue growth (1 year) | 26.0% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.